Concurrent use of omalizumab and dupilumab in a 47‐year‐old woman with chronic spontaneous urticaria and atopic dermatitis

Holm, Jesper Grønlund; Sørensen, Jennifer Astrup; Thomsen, Simon Francis

doi:10.1111/ijd.16009

Cited by 5 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic spontaneous urticaria (CSU) entails the absence of identified causes of urticaria and can be highly debilitating and recalcitrant to standard treatments. A total of 14 patients were reported that had failed standard therapies with antihistamines, omalizumab and/or ciclosporin and were subsequently treated with dupilumab (12/14) or a combination of dupilumab and omalizumab (2/14) ( Table 5 ) [ 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 ]. Complete sustained resolutions were reported in 10/14 patients by clinical evaluation and the 7-day urticaria activity score (UAS7) or urticaria control test (UCT); a UAS7 of 0 was reported in 5 of these cases.…”

Section: Resultsmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

show abstract

Section: Resultsmentioning

confidence: 99%

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…None of our patients, as of now, discontinued their sgAH or omalizumab treatment, because another treatment had to be initiated. This includes other biologics [31][32][33][34].…”

Section: The Role Of the Onset Of Another Disease Or Intake Of A New ...mentioning

confidence: 99%

Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know

et al. 2023

View full text Add to dashboard Cite

In chronic spontaneous urticaria (CSU), wheals, angioedema, or both appear spontaneously for > 6 weeks. Current recommended treatment options for urticaria target mast cell mediators such as histamine, or activators, such as autoantibodies. The goal of CSU treatment is to treat the disease until it is gone as effectively and safely as possible. As no cure is available for CSU as of now, the treatment is aimed at continuously suppressing disease activity, with complete control of the disease and a normalization of quality of life. To achieve this, pharmacological treatment should be continued until no longer needed. Treatment of CSU should follow the basic principles of treating as much as needed and as little as possible taking into consideration that the activity of the disease may vary. Since CSU is a disease with spontaneous remission, it is hard to tell, in patients with complete control and no signs or symptoms, when medication is no longer needed. The current international guideline for urticaria suggests that the treatment can be stepped down once a patient is free of signs and symptoms. Other reasons for stepping down the treatment of CSU patients include safety concerns or issues, pregnancy or wanting to become pregnant, and economic factors. As of now, it is unclear over which period, with what intervals and with which dosages CSU treatment should be stepped down. Guidance on this is needed for all recommended therapies: (i) standard-dosed secondgeneration H1-antihistamine (sgAH), (ii) higher than standard-dosed sgAH, (iii) standard-dosed omalizumab, (iv) higher than standard-dosed omalizumab, and (v) cyclosporine. However, there is a lack of controlled trials on the step down and discontinuation of these treatments. Here, we aim to provide a summary of what is known and what needs to be investigated in further studies, based on our own experience and real-world evidence.

show abstract

“…To date, several case reports have shown the efficacy of dupilumab therapy in CSU patients, mostly in patients with concurrent atopic dermatitis [ 5 ]. In addition, a case report of a patient with CSU and atopic dermatitis demonstrated successful simultaneous therapy with omalizumab and dupilumab for both conditions [ 6 ].…”

Section: Case Reportmentioning

confidence: 99%

Case report: Severe chronic spontaneous urticaria successfully treated with omalizumab and dupilumab

Puxkandl¹,

Hoetzenecker²,

Altrichter³

2023

ALS

View full text Add to dashboard Cite

Urticaria is a disease triggered by mast cells and characterized by recurrent symptoms such as wheals and/or angioedema. Most patients benefit from treatment with antihistamines (AH) or, if not effective enough, from additional therapy with omalizumab, which leads to significant symptom relief. Here we present a patient with therapy-resistant chronic spontaneous urticaria treated with AH, omalizumab, and glucocorticosteroids. The subsequent recommended therapy according to the current guideline, cyclosporine A, was contraindicated in this patient. Therefore, therapy with dupilumab was initiated, resulting in a complete control of symptoms. In this case report, we present a case of successful dual therapy with omalizumab and dupilumab.

show abstract

Concurrent use of omalizumab and dupilumab in a 47‐year‐old woman with chronic spontaneous urticaria and atopic dermatitis

Cited by 5 publications

References 1 publication

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know

Case report: Severe chronic spontaneous urticaria successfully treated with omalizumab and dupilumab

Contact Info

Product

Resources

About